Thalidomide in Combination With Temodar in Patients With Neuroendocrine Tumors

NCT00165230 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

32

Enrollment

OTHER

Sponsor class

Conditions

Neuroendocrine Tumor

Interventions

DRUG: Thalidomide
DRUG: Temodar

Sponsor

Dana-Farber Cancer Institute

Collaborators

[object Object]
[object Object]
[object Object]